Tailoring early-phase clinical trial design to address multiple research objectives

Area of Science:

• Oncology
• Immunotherapy
• Clinical Trial Design

Background:

• Novel early-phase trial designs are crucial for refining cancer drug regimens.
• There is a need for adaptive strategies to manage multiple research objectives efficiently.
• Current oncology drug development requires innovative approaches for combination therapies.

Purpose of the Study:

• To describe a model-based adaptive design strategy for early-phase oncology trials.
• To identify optimal immunotherapy regimens using multiple endpoints and cohorts.
• To facilitate the acceptance of novel designs in early drug development.

Main Methods:

• Developed a model-based adaptive design for a multi-cohort trial.
• Evaluated safety and immunogenicity of cancer vaccines combined with CD40 and CD27 antibodies.
• Assessed immune response compared to optimal controls in melanoma patients.

Main Results:

• The proposed adaptive design is practical for combined immunotherapy regimens.
• The design addresses multiple objectives within multiple cohorts.
• The strategy aids in selecting optimal regimens for further development.

Conclusions:

• Adaptive designs are essential for advancing cancer immunotherapy.
• Incorporating multiple endpoints and combination therapies can improve efficacy and reduce toxicity.
• Novel trial designs are key to future oncology drug development success.